ABIVAX Upcoming Events

2017 Financial Results to be announced on March 16, 2018

PARIS--()--Regulatory News:

ABIVAX (Paris:ABVX) (Euronext Paris: FR0012333284 – ABVX), a biotechnology company harnessing the immune system to develop a functional cure for HIV and treatments for inflammatory/autoimmune diseases and cancer, today announces that its senior management team will participate in upcoming events for investors and business development professionals.

  • March 12-14, 2018: BIO-Europe Spring in Amsterdam
    Prof. Hartmut Ehrlich, M.D., CEO ABIVAX, will give a corporate update presentation on ABIVAX on Tuesday, March 13 at 11:00 in room E105
  • March 16, 2018: Full Year 2017 Financial Results
  • March 19-20, 2018: BIO Asia International Conference in Tokyo
  • April 8-10, 2018: H.C. Wainwright Global Life Sciences Conference in Monaco

About ABIVAX (www.abivax.com/en)

ABIVAX is mobilizing the body’s natural immune machinery to treat patients with viral infections, autoimmune diseases and cancer. A clinical-stage company, ABIVAX leverages its antiviral and immune enhancing platforms to optimize candidates to cure HIV and treat inflammatory bowel diseases and liver cancer. ABIVAX is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo : ABVX). More information on the company is available at www.abivax.com.

Follow us on Twitter @ABIVAX_

Contacts

ABIVAX
Finance
Didier Blondel
didier.blondel@abivax.com
+33 1 53 83 08 41
or
Press Relations France
ALIZE RP
Caroline Carmagnol/Aurore Gangloff
abivax@alizerp.com
+33 6 64 18 99 59
or
Investors Relations
LifeSci Advisors
Chris Maggos
chris@lifesciadvisors.com
+41 79 367 6254
or
Press Relations US
LifeSci Public Relations
Matt Middleman, M.D.
matt@lifescipublicrelations.com
+1 646 627 8384
or
Investors and Press Relations Germany
MC Services AG
Anne Hennecke
anne.hennecke@mc-services.eu
+49 211 529 252 22

Contacts

ABIVAX
Finance
Didier Blondel
didier.blondel@abivax.com
+33 1 53 83 08 41
or
Press Relations France
ALIZE RP
Caroline Carmagnol/Aurore Gangloff
abivax@alizerp.com
+33 6 64 18 99 59
or
Investors Relations
LifeSci Advisors
Chris Maggos
chris@lifesciadvisors.com
+41 79 367 6254
or
Press Relations US
LifeSci Public Relations
Matt Middleman, M.D.
matt@lifescipublicrelations.com
+1 646 627 8384
or
Investors and Press Relations Germany
MC Services AG
Anne Hennecke
anne.hennecke@mc-services.eu
+49 211 529 252 22